Dextrose

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Only for intravenous infusion. ( 2.1 )
• Infusion rate depends on the age, weight, clinical and metabolic conditions of the patient and concomitant therapy. See full prescribing information for information on preparation, administration, dosing considerations. ( 2.1 , 2.2 , 2.3 ) 2.1 Important Administration Instructions Dextrose Injection (5% and 10%) is intended for intravenous use.
• Use a peripheral vein to administer if the final dextrose concentration is 5% or less and the osmolarity is less than 900 mOsm/L.
• Consider using a central vein to administer hypertonic solutions with osmolarity of 900 mOsm/L or greater to
• avoid venous irritation [ see Warnings and Precautions (5.4 )].
• Avoid administering Dextrose Injection (5% and 10%) simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis. If there is only a single IV access, flush the line thoroughly with normal saline before and after blood product administration.
• Use of a final filter is recommended during administration of parenteral solutions, where possible.
• It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.
• Use promptly; do not store solutions containing additives.
• Discard the unused portion.
• To determine if chemotherapy agents are compatible with Dextrose solutions, consult the specific chemotherapy agent prescribing information to determine if Dextrose is the appropriate diluent. 2.2 Important Preparation Information Visually inspect the Dextrose Injection (5% and 10%) for particulate matter and discoloration. Do not administer Dextrose Injection (5% and 10%) if the solution is cloudy, there are precipitates, or the container is damaged. To reduce the risk of air embolism, adhere to the following preparation instructions for Dextrose Injection (5% and 10%):
• Use a non-vented infusion set or close the vent on a vented set.
• Use a dedicated line without any connections (do not connect flexible containers in series).
• The use of pressure infusion is not recommended as a method to increase flow rates. However, if pressure infusion is required, ensure that any air within the bag is fully evacuated prior to initiation of infusion.
• If using a pumping device to administer Dextrose Injection (5% and 10%), turn off the pump before the container is empty. To Open
• Do not remove from overpouch until ready to use.
• Tear overwrap down side at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.
• Visually inspect the container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Evaluate the following:
• o If the outlet port protector is damaged, detached, or not present, discard container. o Check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals. o Check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard container. Preparation for Administration 1. Suspend container from eyelet support. 2. Remove protector from outlet port at bottom of container. 3. Attach administration set. Refer to complete directions accompanying set. To Add Medication
• Additives may be incompatible. Complete information is not available.
• Do not use additives known or determined to be incompatible.
• Consult with pharmacist, if available. If, in the informed judgment of the healthcare provider, it is deemed advisable to introduce additives, use aseptic technique.
• When introducing additives, consult the instructions for use of the medication to be added and other relevant literature.
• Before adding a substance or medication, verify that it is soluble and/or stable in Dextrose Injection and that the pH range of Dextrose Injection is appropriate. To Add Medication Before Solution Administration 1. Prepare medication site. 2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. 3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. 4. After addition, check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals. To Add Medication During Solution Administration 1. Close clamp on the set. 2. Prepare medication site. 3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. 4. Remove container from IV pole and/or turn to an upright position. 5. Evacuate both ports by squeezing them while container is in the upright position. 6. Mix solution and medication thoroughly. 7. After addition, check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals,
• do not use. 8. Return container to in-use position and continue administration. 2.3 Dosage Considerations The choice of dextrose concentration, rate, and volume depends on the age, weight, clinical and metabolic conditions of the patient and concomitant therapy. Dextrose Injection (5% and 10%) patients’ tolerance of dextrose, especially for premature infants with low birth weight. Increase the infusion rate gradually as needed; frequently monitor blood glucose concentrations to
• avoid hyperglycemia [ see Warnings and Precautions (5.2 ), Use in Specific Populations (8.4)].

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

• Dextrose Injection (5% and 10%) is indicated in pediatric patients as a source of water and calories, and may also be used as a diluent for reconstitution of a powder or liquid drug product.
• Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia.
• Therefore, they need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to
• avoid potential long-term adverse effects.
• Dextrose Injection (5% and 10%) can cause imbalances in fluid and electrolytes in pediatric patients and requires close monitoring of volume status and plasma electrolyte concentrations, particularly in pediatric patients who may have impaired ability to regulate fluids and electrolytes.
• Pediatric patients are at increased risk for developing hyponatremic encephalopathy [ see Warnings and Precautions (5.5 , 5.6 )].
• In very low birth weight infants, excessive or rapid administration of Dextrose Injection (5% and 10%) may result in increased serum osmolality and risk of intracerebral hemorrhage.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Dextrose Injection (5% and 10%) has not been studied insufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
• Geriatric patients are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [ see Warnings and Precautions (5.5 )].
• Other reported clinical experience has not identified differences in responses between the geriatric and younger adult patients.
• In general, the infusion rate for geriatric patients should start low and be titrated up cautiously, reflecting their greater risk for electrolyte abnormalities and fluid overload.
• Dextrose Injection (5% and 10%) is known to be substantially excreted by the kidney, and the risk of adverse reactions to Dextrose Injection (5% and 10%) may be greater in patients with impaired renal function.
• Because geriatric patients are more likely to have impaired renal function, care should be taken in selection of infusion rate and patients should be closely monitored during Dextrose Injection (5% and 10%) treatment.

Quoted from the official label, section “Geriatric Use”.

Side effects

• The following clinically significant adverse reactions are described elsewhere in the labeling:
• Neonatal Hypoglycemia [ see Warnings and Precautions (5.1)]
• Hyperglycemia and Hyperosmolar Hyperglycemic State [ see Warnings and Precautions (5.2)]
• Hypersensitivity Reactions [ see Warnings and Precautions (5.3)]
• Phlebitis and Thrombosis [ see Warnings and Precautions (5.4)]
• Hyponatremia [ see Warnings and Precautions (5.5 )]
• Electrolyte Imbalance and Fluid overload [ see Warnings and Precautions (5.6)]
• Refeeding syndrome [ see Warnings and Precautions (5.7 )] The following adverse reactions associated with the use of dextrose injection were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure. Administration site conditions :
• blister, erythema, extravasation, pain, phlebitis, vein damage, thrombosis Immune system disorders :
• anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritis, pyrexia, rash Cardiovascular disorders :
• cyanosis, volume overload The most common adverse reactions are, hyperglycemia, hypersensitivity reactions, hyponatremia, infection both systemic and at the injection site, vein thrombosis or phlebitis, and electrolyte imbalance. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• Manufactured by, Packed by, Distributed by:
• Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA Baxter and Viaflex are trademarks of Baxter International Inc.

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS Injection:
• 5% (5 g/100 mL) (50 mg/mL) of dextrose hydrous a clear, sterile, non-pyrogenic solution in single-dose partial-fill flexible containers:
• 25 mL, 50 mL, 100 mL, 250 mL, 500 mL, and 1000 mL
• 10% (10 g/100 mL) (100 mg/mL) of dextrose hydrous in sing-dose partial-fill flexible containers:
• 250 mL, 500 mL, and 1000 mL Injection:
• 5% (5 g/100 mL) (50 mg/mL) of dextrose hydrous in single-dose partial-fill flexible containers:
• 25 mL, 50 mL, 100 mL, 250 mL, 500 mL, and 1000 mL. ( 3 )
• 10% (10 g/100 mL)(100 mg/mL) of dextrose hydrous in partial-fill flexible containers:
• 250 mL, 500 mL, and 1000 mL. ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• Dextrose Injection (5% and 10%), USP is clear, colorless, sterile solutions of dextrose supplied in a single-dose, partial-fill flexible containers.
• Product Description Size Code NDC Dextrose Injection 5%, USP (5 g/100 mL) (50 mg/mL) 25 mL Quad pack 2B0080 0338-0017-10 50 mL Single pack Quad pack Multi pack 2B0086 2B0081 2B0088 0338-0017-41 0338-0017-11 0338-0017-31 100 mL Single pack Quad pack Multi pack 2B0087 2B0082 2B0089 0338-0017-48 0338-0017-18 0338-0017-38 250 mL 500 mL 1000 mL 2B0062 2B0063 2B0064 0338-0017-02 0338-0017-03 0338-0017-04 Dextrose Injection 10%, USP (10 g/100 mL) (100 mg/mL) 250 mL 500 mL 1000 mL 2B0162 2B0163 2B0164 0338-0023-02 0338-0023-03 0338-0023-04 Do not remove container from the overwrap until intended for use.
• Use the product immediately after mixing and the introduction of additives.
• Exposure of pharmaceutical products to heat should be minimized.
• Avoid excessive heat.
• It is recommended the product be stored at room temperature (25°C/77°F); brief exposure up to 40°C/104°F does not adversely affect the product.

Quoted from the official label, section “How Supplied”.

What is in it

• Dextrose Injection, 5% and 10% USP are sterile, non-pyrogenic solutions of Dextrose, USP in Water for Injection in a polyvinylchloride flexible plastic container for intravenous administration as a source of water and calories. Partial-fill containers, designed to facilitate admixture when necessary, are available in 25 mL, 50 mL, 100 mL, 250 mL, 500 mL, and 1000 mL sizes. See Table 1 for the content and characteristics of this solution. The solution contains no bacteriostatic, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. The pH range is 4.0 (3.2 to 6.5). Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Table 1. Contents and Characteristics of Dextrose Injection 5% and 10%, USP Strength Fill Volume Amount of Dextrose Hydrous per Container kcal Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous per Container Osmolarity (mOsmol per liter) Dextrose Injection 5%, USP (0.05 grams/mL) 25 mL Quad pack 1.25 grams 4.25 252 50 mL Single pack Quad pack Multi pack 2.5 grams 8.5 252 100 mL Single pack Quad pack Multi pack 5 grams 17 252 250 mL 12.5 grams 42.5 252 500 mL 25 grams 85 252 1000 mL 50 grams 170 252 Dextrose Injection 10%, USP (0.1 grams/mL) 250 mL 25 grams 85 505 500 mL 50 grams 170 505 1000 mL 100 grams 340 505 Dextrose, USP is chemically designated D-glucose, monohydrate (C 6 H 12 O 6
• H 2 O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:
• Water for Injection, USP is chemically designated H2O. Dextrose is derived from corn. The VIAFLEX Plus plastic container is fabricated from polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution. Solutions in contact with the plastic container can leach out certain of its chemical components in small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. The safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies. Dextrose Hydrous Structural Formula

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

42 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Dextrose Monohydrate